Transgene SA (EPA:TNG)
France · Delayed Price · Currency is EUR 0.7000
-0.0140 (-1.96%)
Oct 2, 2026, 5:35 PM CET
Transgene Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 0.41 | 0.14 | 0.04 | 1.18 | 3.13 | 9.99 |
Other Revenue | 5.22 | 7.07 | 6.32 | 6.72 | 7.22 | 7.25 |
| 5.62 | 7.21 | 6.35 | 7.9 | 10.34 | 17.24 | |
Revenue Growth | -25.76% | 13.49% | -19.58% | -23.63% | -40.00% | 80.08% |
Cost of Revenue | 33.9 | 33.9 | 34.28 | 29.59 | 32.17 | 32.88 |
Gross Profit | -28.27 | -26.69 | -27.93 | -21.69 | -21.82 | -15.64 |
Selling, General & Admin | 7.65 | 7.31 | 7.76 | 6.99 | 7.91 | 7.37 |
Research & Development | -2.49 | - | - | - | - | - |
Other Operating Expenses | 1.3 | 1.06 | -0.03 | 1.34 | 0.16 | 0.68 |
Operating Expenses | 6.47 | 8.37 | 7.73 | 8.32 | 8.07 | 8.05 |
Operating Income | -34.74 | -35.06 | -35.66 | -30.01 | -29.9 | -23.7 |
Interest Expense | -1.31 | -1.31 | -1.68 | -0.17 | -0.8 | -0.46 |
Interest & Investment Income | 0.57 | 0.57 | 2.59 | 8.08 | 2.48 | 0.8 |
Currency Exchange Gain (Loss) | -1.35 | -1.35 | 0.78 | -0.19 | 0.11 | 0.17 |
Other Non Operating Income (Expenses) | 2.92 | -0.38 | - | - | -19.03 | -0.13 |
EBT Excluding Unusual Items | -33.9 | -37.52 | -33.97 | -22.29 | -47.14 | -23.32 |
Gain (Loss) on Sale of Investments | - | - | - | - | 14.35 | 3.79 |
Gain (Loss) on Sale of Assets | - | - | -0 | -0.04 | -0.01 | -0 |
Pretax Income | -33.9 | -37.52 | -33.97 | -22.33 | -32.8 | -19.54 |
Earnings From Continuing Operations | -33.9 | -37.52 | -33.97 | -22.33 | -32.8 | -19.54 |
Net Income | -33.9 | -37.52 | -33.97 | -22.33 | -32.8 | -19.54 |
Net Income to Common | -33.9 | -37.52 | -33.97 | -22.33 | -32.8 | -19.54 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 211 | 145 | 117 | 101 | 100 | 91 |
Shares Outstanding (Diluted) | 211 | 145 | 117 | 101 | 100 | 91 |
Shares Change | 61.52% | 23.88% | 15.98% | 1.09% | 9.21% | 11.04% |
EPS (Basic) | -0.16 | -0.26 | -0.29 | -0.22 | -0.33 | -0.21 |
EPS (Diluted) | -0.16 | -0.26 | -0.29 | -0.22 | -0.33 | -0.21 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -39.86 | -37.89 | -26.61 | -37.34 | -21.8 | -26.58 |
Free Cash Flow Per Share | -0.19 | -0.26 | -0.23 | -0.37 | -0.22 | -0.29 |
Gross Margin | - | - | - | -274.53% | -210.98% | -90.75% |
Operating Margin | -617.69% | -486.25% | -561.23% | -379.90% | -289.04% | -137.45% |
Profit Margin | -602.74% | -520.44% | -534.72% | -282.63% | -317.13% | -113.32% |
Free Cash Flow Margin | -708.73% | -525.49% | -418.92% | -472.63% | -210.75% | -154.19% |
EBITDA | -33.4 | -33.73 | -34.37 | -28.44 | -28.21 | -21.24 |
EBITDA Margin | - | - | - | - | -272.74% | -123.22% |
D&A For EBITDA | 1.34 | 1.33 | 1.28 | 1.57 | 1.69 | 2.45 |
EBIT | -34.74 | -35.06 | -35.66 | -30.01 | -29.9 | -23.7 |
EBIT Margin | - | - | - | - | -289.04% | -137.45% |
Revenue as Reported | 5.62 | 7.21 | 6.35 | 7.9 | 10.34 | 17.41 |